相关实验视频

Updated: Jun 8, 2025

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Glycemic Impact on Knee Osteoarthritis Symptoms on Physical, Radiographic, and Inflammatory Markers among Individuals Aged 50 and Over with Diabetes

Published on: March 7, 2025

血糖控制对糖尿病患者提取后愈合的影响

Jegan M¹, A Saneem Ahamed², Vijaya Lakshmi G²

¹Dentistry, Priyadarshini Dental College and Hospital, Chennai, IND.

|November 7, 2024

概括

这项研究发现,糖尿病患者的随机血糖水平在151-240毫克/分升之间,与≤150毫克/分升水平相比,没有显著影响提取后的伤口愈合. 虽然一些轻微的并发症增加了,但整体愈合结果仍然相似.

科学领域:

在口腔外科手术.
内分泌学在内分泌学.
伤口治愈研究研究伤口治愈研究

背景情况:

糖尿病,以高血糖为特征,通常会损害牙提取后的伤口愈合.
像感染和延迟恢复这样的并发症在糖尿病患者中很常见.
血糖控制对愈合结果的具体影响需要进一步阐明.

研究的目的:

为了比较胰岛素依赖的糖尿病患者在提取后的伤口愈合,其血糖水平控制良好 (RBS ≤150 mg/dL) 与中度控制 (RBS 151-240 mg/dL).
评估血糖控制与临床结果 (如疼痛,出血,感染和口腔干燥) 之间的关联.

主要方法:

对100名依赖胰岛素的糖尿病患者进行前性观察性研究.
患者根据随机血糖 (RBS) 分为两组:A组 (≤150 mg/dL) 和B组 (151-240 mg/dL).
临床结果包括疼痛,出血,感染和伤口尺寸在提取后的1,7和14天被评估.

主要成果:

高血糖水平 (151-240 mg/dL) 与疼痛和出血增加有关,但没有显著改变整体愈合结果.
与B组相比,A组 (RBS ≤150 mg/dL) 显示出更好的愈合状态.
在两个血糖控制组之间没有观察到治疗结果的显著差异.

结论:

151-240 mg/dL之间的血糖水平与≤150 mg/dL水平相比,在糖尿病患者中没有显著影响提取后的伤口愈合.
虽然在这个范围内血糖升高可能不会阻碍愈合,但管理糖尿病仍然至关重要,以防止不良后果.
需要进一步的研究来确定最佳的血糖范围,以便在糖尿病患者中改善伤口愈合.

关键词:

牙抽取牙抽取牙抽取在糖尿病中,糖尿病是血糖类的.葡萄糖水平的高血糖水平.提取后的并发症伤口愈合伤口愈合

更多相关视频

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

A Protocol for Constructing a Rat Wound Model of Type 1 Diabetes

Published on: February 17, 2023

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

A Novel Approach to Monitoring Graft Neovascularization in the Human Gingiva

Published on: January 12, 2019

相关概念视频

Hypoglycemia and Glucagon

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...

Diabetes: Management and Pharmacotherapy

Diabetes: Management and Pharmacotherapy

The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...

Diabetes Mellitus: Type 2 and Gestational

Diabetes Mellitus: Type 2 and Gestational

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

Oral Hypoglycemic Agents: Glinides

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...